Thursday, December 18, 2014 11:38:06 AM
I'm long-time shareholder...but sometimes, my level of irritation just gets so high, I gotta vent a little.
For example, I think it's a reasonably safe assumption that the odds greatly favor bavi approval in phase III trial. The aims and goals set for the trial appear to be easily within reach, and wherever you set the time-line for completion, it appears to be in order.
So why such a low pps? The "greed factor" that would apparently lead to increasing share price just doesn't seem to apply here.
With a biotech company, one hears a lot about the importance of "depth of pipeline". When you consider imaging, beta-bodies, broad spectrum of application, and other things I consider germane to "pipeline", we're apparently in good shape here, too.
So why such a low pps? Seems to me we're in a lot better shape with pipeline than many others with higher valuation.
Manufacturing capability is something we have that many, many others do not. Avid has shown leadership in developing more efficient production, has good operating margin, and has shown some good, steady growth in past years. If Avid were a free-standing entity, what would it be worth on the stock market? Seems to me it would be worth more than the value it currently has as a portion of our stock price.
Intellectual property value is another facet of valuation in the biotech world...and here, too...I fail to see why ours is considered so unworthy of higher pps. It appears to me that with the growing recognition of immunotherapy in cancer, and allegedly being in the forefront of this field, we should be accorded a higher pps than where we currently stagnate.
Marketability of bavi, in my mind, is exceptional. Everybody recognizes that approval in a growth field means increasing revenues. But our pps, IMO, does not reflect what approval would mean to our bottom line.
Much has been said about our BOD and about lack of credibility. And about the level of industry experience of BOD members. Well, I think being a co-inventor on bavi with Thorpe gives SK enough gravitas to make up for some of that. After all, who makes a better advocate for a product than the guys who came up with it? Furthermore, a better mousetrap is still a better mousetrap, no matter how bumbling the hands that hold it.
Guys, I'm sorry to bitch about my investment. But sometimes, ya just gotta let of some steam.
Recent CDMO News
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM